Beurs gesloten -
Andere beurzen
|
Nabeurs 01:18:22 | |||
4,82 USD | -12,20% | 4,895 | +1,56% |
23/04 | Aankomende grote tech-inkomsten stuwen Exchange-Traded Funds, aandelenfutures dinsdag vóór de bel | MT |
23/04 | Amerikaanse FDA keurt blaaskankertherapie van ImmunityBio goed | RE |
Omzet 2024 * | 9,68 mln. 9,02 mln. | Omzet 2025 * | 84,68 mln. 78,94 mln. | Marktkapitalisatie | 3,26 mld. 3,04 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -459 mln. -428 mln. | Nettowinst (verlies) 2025 * | -305 mln. -284 mln. | EV/omzet 2024 * | 337 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 38,5 x |
K/w-verhouding 2024 * |
-7,09
x | K/w-verhouding 2025 * |
-10,7
x | Werknemers | 628 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 20,33% |
Recentste transcriptie over ImmunityBio, Inc.
1 dag | +1,56% | ||
1 week | -8,02% | ||
Lopende maand | -10,24% | ||
1 maand | -20,59% | ||
3 maanden | +49,46% | ||
6 maanden | +167,78% | ||
Lopend jaar | -3,98% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Richard Adcock
CEO | Chief Executive Officer | 55 | 01-10-20 |
Founder | 71 | 01-12-14 | |
David Sachs
DFI | Director of Finance/CFO | 46 | 01-07-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 71 | 01-12-14 | |
Cheryl L. Cohen
BRD | Director/Board Member | 58 | 01-06-19 |
Wesley Clark
BRD | Director/Board Member | 78 | 24-02-21 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.04% | 0 M€ | 0,00% | - | |
0.04% | 0 M€ | 0,00% | - | |
0.02% | 2 M€ | -.--% |
Datum | Koers | Variatie | Volume |
---|---|---|---|
24-04-24 | 4,82 | -12,20% | 7 938 366 |
23-04-24 | 5,49 | +11,13% | 30 697 001 |
22-04-24 | 4,94 | -6,26% | 5 468 509 |
19-04-24 | 5,27 | +7,33% | 4 571 786 |
18-04-24 | 4,91 | -6,30% | 3 516 802 |
uitgestelde koers Nasdaq, 24 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,98% | 3,26 mld. | |
-1,51% | 104 mld. | |
+3,22% | 97,42 mld. | |
+1,57% | 22,2 mld. | |
-16,53% | 21,23 mld. | |
-8,79% | 18,33 mld. | |
-42,33% | 16,35 mld. | |
-20,09% | 15,06 mld. | |
+5,47% | 13,98 mld. | |
+28,85% | 11,66 mld. |